Amgen Pays Array $60 Million Upfront For Its Phase One Type 2 Diabetes Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal for ARRY-403 includes up to $666 million in milestones, a two-year research-funding agreement and U.S. co-promotion option.
You may also be interested in...
Deals Of The Week: Isis Rethinks Its Partnering Strategy
Capitalizing on the interest that partners are showing in its beefed-up antisense pipeline, Isis has reset its partnering strategy to maximize the value of each asset. In other developments, Ensemble snagged Novartis in a discovery collaboration and Amgen returned glucokinase activator AMG 151 to Array.
China’s Hua Medicine Licenses Worldwide Rights To Roche Diabetes Compound, More Deals On The Way
Chinese startup Hua Medicine kicks off its in-licensing strategy with an IND-ready glucokinase activator from Roche.
China’s Hua Medicine Licenses Worldwide Rights To Roche Diabetes Compound, More Deals On The Way
Chinese startup Hua Medicine kicks off its in-licensing strategy with an IND-ready glucokinase activator from Roche.